Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load

1992 ◽  
pp. 259-261
Author(s):  
R. M. L. Brouwer ◽  
W. Weimar ◽  
A. H. M. M. Balk
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder

scholarly journals Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study

2022 ◽  
Vol 11 (2) ◽  
pp. 322
Author(s):  
Rabea Asleh ◽  
Darko Vucicevic ◽  
Tanya M. Petterson ◽  
Walter K. Kremers ◽  
Naveen L. Pereira ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Univariate Analysis ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Inhibitors ◽  
Lymphoid Cells ◽  
Post Transplant ◽  
Barr Virus ◽  
Increased Risk ◽  
Epstein Barr

Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid cells; thus, their use for immunosuppression after heart transplantation (HT) may reduce post-transplant lymphoproliferative disorder (PTLD) risk. This study sought to investigate whether the sirolimus (SRL)-based immunosuppression regimen is associated with a decreased risk of PTLD compared with the calcineurin inhibitor (CNI)-based regimen in HT recipients. We retrospectively analyzed 590 patients who received HTs at two large institutions between 1 June 1988 and 31 December 2014. Cox proportional-hazard modeling was used to examine the association between type of primary immunosuppression and PTLD after adjustment for potential confounders, including Epstein–Barr virus (EBV) status, type of induction therapy, and rejection. Conversion from CNI to SRL as primary immunosuppression occurred in 249 patients (42.2%). During a median follow-up of 6.3 years, 30 patients developed PTLD (5.1%). In a univariate analysis, EBV mismatch was strongly associated with increased risk of PTLD (HR 10.0, 95% CI: 3.8–26.6; p < 0.001), and conversion to SRL was found to be protective against development of PTLD (HR 0.19, 95% CI: 0.04–0.80; p = 0.02). In a multivariable model and after adjusting for EBV mismatch, conversion to SRL remained protective against risk of PTLD compared with continued CNI use (HR 0.12, 95% CI: 0.03–0.55; p = 0.006). In conclusion, SRL-based immunosuppression is associated with lower incidence of PTLD after HT. These findings provide evidence of a benefit from conversion to SRL as maintenance therapy for mitigating the risk of PTLD, particularly among patients at high PTLD risk.

Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation

2015 ◽  
Vol 36 (8) ◽  
pp. 1748-1753 ◽  
Author(s):  
Don Hayes ◽  
Christopher K. Breuer ◽  
Edwin M. Horwitz ◽  
Andrew R. Yates ◽  
Joseph D. Tobias ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Posttransplant Lymphoproliferative Disorder

scholarly journals Late-Onset Posttransplant Lymphoproliferative Disorder Results in Jejunal Stricture Managed with Endoscopic Dilation

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Steven Park ◽  
John Miller ◽  
Janice Cheong ◽  
Asad Ullah ◽  
Lawrence Saubermann ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Late Onset ◽  
Orthotopic Heart Transplantation ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Case Presentation ◽  
Jejunal Stricture ◽  
Bowel Stricture ◽  
Rare Diagnosis ◽  
Endoscopic Balloon

Background. Late-onset posttransplant lymphoproliferative disorder (PTLD) after orthotopic heart transplantation is rare. Case Presentation. We present a rare diagnosis of small bowel stricture caused by healed lymphomatous ulcers in a patient with orthotopic heart transplantation and PTLD diagnosed 25 years after initial transplantation. We also demonstrate successful endoscopic balloon dilations that improved the patient’s obstructive symptoms. Conclusion. It is important to consider stricture from healed lymphomatous ulcers in posttransplant patients presenting with obstructive symptoms.

EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation

2003 ◽  
Vol 242 (1) ◽  
pp. 44-50 ◽  
Author(s):  
Jens Martin Rohrbach ◽  
Stefan Martin Kröber ◽  
Thomas Teufel ◽  
Rolf-Dieter Kortmann ◽  
Manfred Zierhut
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder

An unusual manifestation of post-transplant lymphoproliferative disorder in the lip after pediatric heart transplantation

2012 ◽  
Vol 16 (7) ◽  
pp. E320-E324 ◽  
Author(s):  
C. Chen ◽  
S. Akanay-Diesel ◽  
F. R. Schuster ◽  
D. Klee ◽  
K. G. Schmidt ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Unusual Manifestation ◽  
Post Transplant ◽  
Pediatric Heart Transplantation

A Case of Post-transplantation Lymphoproliferative Disorder (PTLD) Six Months after Heart transplantation Complicated with Small Intestine Perforation after Chemotherapy

2014 ◽  
Vol 20 (10) ◽  
pp. S177
Author(s):  
Daisuke Nitta ◽  
Teruhiko Imamura ◽  
Koichiro Kinugawa ◽  
Eisuke Amiya ◽  
Takeo Fujino ◽  
...  
Keyword(s):  
Small Intestine ◽  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Post Transplantation

Usefulness and Limitations of Rituximab in Managing Patients With Lymphoproliferative Disorder After Heart Transplantation

2012 ◽  
Vol 10 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Mario Senechal ◽  
Sabrina Demers ◽  
Bernard Cantin ◽  
Christine Bourgault ◽  
Marie-Helene Leblanc ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder
Sign in / Sign up

Export Citation Format

Share Document